{"doi":"10.1016/j.ekir.2021.03.869","title":"POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR &amp;lt;30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL","abstract":"The DAPA-CKD trial demonstrated that the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduced the risk of kidney failure, and prolonged survival in participants with chronic kidney disease (CKD) with and without type 2 diabetes. The DAPA-CKD trial enrolled patients with estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2. Little is known about the efficacy and safety of SGLT2 inhibitors in patients with eGFR <30 ml/min/1.73m2. We therefore assessed and compared effects of dapagliflozin on major kidney and cardiovascular outcomes in patients with an eGFR above or below 30 ml/min/1.73m2.","journal":"Kidney International Reports","year":2021,"id":217331,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9523,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":814150,"name":"Priya Vart","orcid":"0000-0001-5576-820X","position":1,"is_corresponding":false},{"id":814151,"name":"Niels Jongs","orcid":"0000-0002-0882-3656","position":2,"is_corresponding":false},{"id":283029,"name":"Robert D. Toto","orcid":"0000-0001-9531-1749","position":3,"is_corresponding":false},{"id":814152,"name":"José Luis Górriz","orcid":"0000-0002-1134-9051","position":4,"is_corresponding":false},{"id":289676,"name":"Fan Fan Hou","orcid":"0000-0003-3117-7418","position":5,"is_corresponding":false},{"id":2612,"name":"John J.V. McMurray","orcid":"0000-0002-6317-3975","position":6,"is_corresponding":false},{"id":814153,"name":"Ricardo Correa‐Rotter","orcid":"0000-0003-0100-8285","position":7,"is_corresponding":false},{"id":42050,"name":"Peter Rossing","orcid":"0000-0002-1531-4294","position":8,"is_corresponding":false},{"id":814154,"name":"C. David Sjöström","orcid":"0000-0002-8380-9766","position":9,"is_corresponding":false},{"id":814155,"name":"Bergur V. Stefánsson","orcid":"0000-0002-0777-5373","position":10,"is_corresponding":false},{"id":226404,"name":"Anna Maria Langkilde","orcid":"0000-0002-1696-9356","position":11,"is_corresponding":false},{"id":255779,"name":"David C. Wheeler","orcid":"0000-0003-0745-3478","position":12,"is_corresponding":false},{"id":232682,"name":"Hiddo J.L. Heerspink","orcid":"0000-0002-3126-3730","position":13,"is_corresponding":false},{"id":11025,"name":"Glenn M. Chertow","orcid":"0000-0002-7599-0534","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:53:20.374789Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}